SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: M. Carver who wrote (948)7/8/1998 9:02:00 AM
From: bill hopkins  Respond to of 1055
 
Nice post, good info re CEO comments more like that are certainly welcome... Stock was unduly punished...4th July airpocket partially due to everyone having gone home...seems to be pushing to recover ...Bill



To: M. Carver who wrote (948)7/8/1998 11:14:00 AM
From: Tulvio Durand  Respond to of 1055
 
Thanks for your informative post. It bears repeating the notable quote from Christine Jacobs: ... "she is confident her company will remain the leader in palladium, which she says kills cancer 3 times faster than iodine" and "We've got an 11-year head start in an industry with significant (regulatory) barriers to entry" That says it all. Tulvio



To: M. Carver who wrote (948)7/8/1998 7:40:00 PM
From: seedy  Read Replies (1) | Respond to of 1055
 
Just some technical info...Palladium may kill cancer cells 3 times faster, but Iodine stays radioactive and "kills" much longer, so Palladium is not always best. In theory, Palladium is used for a faster growing tumor instead of Iodine. There is not a whole lot of long term data on which isotope is better. Time will tell.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News